Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals Recalls Pradaxa Capsules in U.S., Puerto Rico

The firm is recalling one lot of the drug, indicated to reduce the risk of stroke and systemic embolism in patients with NVAF.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that it is conducting a nationwide voluntary recall of a single manufacturing lot of Pradaxa (dabigatran etexilate mesylate), 75mg 60 US, NDC 0597- 0149-54, lot 201900, Exp January 2015. PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).  The recall is limited to this one lot number.

No votes yet
Syndicate content